Allogeneic hematopoietic cell transplant for normal karyotype AML: indirect evidence of selection for adverse molecular profile
M-E M Percival(Stanford University), Robert Lowsky(Stanford University), Judith A. Shizuru(Stanford University), Lü Tian(Shandong University), Linda J. Johnston(Université Bourgogne Franche-Comté), Scott M. Robeson(Indiana University Bloomington), Bruno C. Medeiros(Stanford Medicine), Sally Arai(Stanford Medicine), Ginna G. Laport(Stanford Blood Center), David B. Miklos(Stanford University), RS Negrin(Stanford University), W-K Weng(Stanford University)
Cited by 1
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k